Twist Bioscience Corp is a biotechnology company that focuses on revolutionizing the way synthetic DNA is produced. Utilizing its proprietary synthesis platform, the company specializes in creating high-quality, cost-effective DNA for a variety of applications, including healthcare, agriculture, and industrial biotechnology. The core technology is designed to meet the growing demand for synthetic genetic material, enabling advancements in fields such as gene therapy, personalized medicine, and synthetic biology. By providing tailored DNA solutions, Twist Bioscience aims to accelerate innovation and breakthroughs in life sciences and other industries reliant on genetic engineering.
Cathie Wood, founder and CEO of ARK Investment Management LLC, defended the future of artificial intelligence investments while highlighting Tesla Inc. as a cornerstone of technological innovation during a recent podcast appearance with SoFi's Head of Investment Strategy, Liz Thomas.
Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies.
Twist Bioscience's Q4 results topped estimates, with revenue up 27% YoY. Fiscal 2025 guidance includes revenue growth and a targeted gross margin of 48%.
Twist Bioscience reported a Q3 adjusted EPS loss of $(0.70), surpassing the $(0.77) consensus. With a net loss of $85.6 million and sales at $81.5 million, Twist Bioscience saw a 27.8% year-over-year sales increase. The company also raised its 2024 sales guidance.
In a recent letter to investors, Cathie Wood, the CEO of ARK Invest, highlighted the potential of the company's flagship fund, ARK Innovation ETF, despite its recent underperformance.
